Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorPolichronis, A.en
dc.contributor.authorKatsohis, K.en
dc.contributor.authorGennatas, K.en
dc.contributor.authorToussis, D.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorVassilaros, S.en
dc.contributor.authorSemoglou, C.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorFahantidis, E.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorTsavaris, N.en
dc.contributor.authorKonstantaras, C.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorKolotas, C.en
dc.contributor.authorZamboglou, N.en
dc.contributor.authorTsiliakos, S.en
dc.contributor.authorHainoglou, D.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:25:46Z
dc.date.available2015-11-24T19:25:46Z
dc.identifier.issn0030-2414-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22653
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/mortality/pathologyen
dc.subjectChemotherapy, Adjuvanten
dc.subjectCyclophosphamide/administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosage/adverse effectsen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectMethotrexate/administration & dosage/adverse effectsen
dc.subjectMiddle Ageden
dc.subjectMitoxantrone/administration & dosage/adverse effectsen
dc.subjectRemission Inductionen
dc.subjectSurvival Rateen
dc.titleCyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Studyen
heal.abstract362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p=0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8604240-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000227550-
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1996-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ